ProSomnus (NASDAQ:OSA) reported quarterly sales of $7.84 million which beat the analyst consensus estimate of $7.37 million by 6.35 percent. This is a 35.32 percent increase over sales of $5.79 million the same period last year.
ProSomnus (NASDAQ:OSA) reported quarterly sales of $7.84 million which beat the analyst consensus estimate of $7.37 million by 6.35 percent. This is a 35.32 percent increase over sales of $5.79 million the same period last year.
Save time and jump to the most important pieces.
ProSomnus (NASDAQ:OSA) reported quarterly sales of $7.84 million which beat the analyst consensus estimate of $7.37 million by 6.35 percent. This is a 35.32 percent increase over sales of $5.79 million the same period last year.
Gainers Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. Coeptis Therapeutics (NASDAQ:COEP) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. Titan Pharma (NASDAQ:TTNP) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. BioSig Technologies (NASDAQ:BSGM) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. Iridex (NASDAQ:IRIX) stock in
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report earnings for its fourth quarter. • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.38 per share on revenue of $1.52 billion. • GDS Holdings (NASDAQ:GDS) is likely to report quarterly loss at $0.33 per share on revenue of $357.63 million. • Bragg Gaming Group (NASDAQ:BRAG) is estimated to report quarterly loss at $0.01 per share on revenue of $37.82 million. • BioLine Rx (NASDAQ:BLRX) is expected to report earnings for its fourth quarter. • Zhihu (NYSE:ZH) is li
8-K - ProSomnus, Inc. (0001934064) (Filer)
8-K - ProSomnus, Inc. (0001934064) (Filer)
10-K/A - ProSomnus, Inc. (0001934064) (Filer)
SC 13G - ProSomnus, Inc. (0001934064) (Subject)
SC 13G/A - ProSomnus, Inc. (0001934064) (Subject)
SC 13D/A - ProSomnus, Inc. (0001934064) (Subject)
PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. "This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus® RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory," commented L
4 - ProSomnus, Inc. (0001934064) (Issuer)
4 - ProSomnus, Inc. (0001934064) (Issuer)
4 - ProSomnus, Inc. (0001934064) (Issuer)
PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv
PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth quarter and fiscal year 2023 financial results and provide a business update before market open on Monday, March 18, 2024 at the 36th Annual ROTH Conference and via a live webcast. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Following the call, management will participate in the 36th Annual ROTH Conference, being held March 17-19, 2024. Fourth Quarter and Fisc